Edwards Lifesciences Corp (BSP:E1WL34)
R$ 113.96 +2.97 (+2.68%) Market Cap: 262.75 Bil Enterprise Value: 245.12 Bil PE Ratio: 52.27 PB Ratio: 4.94 GF Score: 90/100

Edwards Lifesciences Corporation at Deutsche Bank HealthCare Summit Transcript

Sep 16, 2026 / 02:00PM GMT
Release Date Price: R$113.96 (+2.68%)
Pito Chickering
Deutsche Bank AG - Research Analyst

Good morning, everyone. Thanks for joining us today. Very pleased to host Edwards Land Sciences.

So, this should be a fun event.

I guess, to start off with, before we start asking questions, do you want to have any sort of opening statements or shall I just get right into this?

Bernard Zovighian
Edwards Lifesciences Corporation - Chief Executive Officer, Director

No, let's get into it.

Good morning, everyone. It's great to be here.

I'm glad you have interest in the company.

We are very pleased about all what we do. We take care of patients in the best way possible. And so we are very proud of the impact we are having.

Questions & Answers

Pito Chickering
Deutsche Bank AG - Research Analyst

So, like Edwards is evolving from basically predominantly a TAVR story for the last four decades into TMTT, which is increasingly part of your growth algorithm. I guess, from a bigger picture, how should investors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot